Meant Issues Guidance for Evaluating Telehealth GLP-1 Providers
As demand for GLP-1 medications surges, the digital health provider Meant has released a checklist of questions intended to help patients navigate the growing market of online weight-loss services.
The rise of telehealth services offering GLP-1 agonists has created a crowded marketplace, complicating the selection process for patients. Meant, a digital health provider, published a guide this week outlining five criteria patients should examine before committing to a subscription-based weight management program.
The guidance emphasizes the need for transparency regarding medical supervision, the origin of the prescribed medications, and the inclusion of long-term lifestyle support. According to the company, patients should verify whether providers facilitate regular blood work and if the clinical team is directly accessible for ongoing medication management.
Industry analysts note that as interest in weight-loss drugs grows, regulatory scrutiny over telehealth platforms has intensified. By providing a framework for evaluation, Meant seeks to differentiate its own operational standards within a sector that has faced criticism for inconsistent prescribing practices and supply chain transparency.
The guidance concludes that patients should prioritize providers who offer comprehensive metabolic monitoring over those focusing exclusively on rapid medication fulfillment.